Shandong Boan Biotechnology Past Earnings Performance
Past criteria checks 2/6
Shandong Boan Biotechnology has been growing earnings at an average annual rate of 31.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 29.4% per year. Shandong Boan Biotechnology's return on equity is 4.4%, and it has net margins of 8.6%.
Key information
31.7%
Earnings growth rate
127.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 29.4% |
| Return on equity | 4.4% |
| Net Margin | 8.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shandong Boan Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 720 | 62 | 323 | 190 |
| 31 Mar 24 | 669 | -29 | 316 | 211 |
| 31 Dec 23 | 618 | -119 | 308 | 231 |
| 30 Sep 23 | 587 | -209 | 305 | 294 |
| 30 Jun 23 | 557 | -298 | 302 | 357 |
| 31 Mar 23 | 536 | -315 | 299 | 379 |
| 31 Dec 22 | 516 | -332 | 296 | 400 |
| 30 Sep 22 | 442 | -291 | 253 | 345 |
| 30 Jun 22 | 367 | -251 | 211 | 289 |
| 31 Mar 22 | 263 | -238 | 153 | 260 |
| 31 Dec 21 | 159 | -225 | 96 | 232 |
Quality Earnings: UJ9 has a high level of non-cash earnings.
Growing Profit Margin: UJ9 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UJ9 has become profitable over the past 5 years, growing earnings by 31.7% per year.
Accelerating Growth: UJ9 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: UJ9 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: UJ9's Return on Equity (4.4%) is considered low.